SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Tyndall AJ, Bannert B, Vonk M et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann. Rheum. Dis. 2010; 69: 180915.
  • 2
    Bryan C, Knight C, Black CM et al. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum. 1999; 42: 26605.
  • 3
    Fransen J, Popa-Diaconu D, Hesselstrand R et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann. Rheum. Dis. 2011; 70: 178892.
  • 4
    Simeon CP, Armadans L, Fonollosa V et al. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann. Rheum. Dis. 1997; 56: 7238.
  • 5
    Joven BE, Almodovar R, Carmona L et al. Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. Semin. Arthritis Rheum. 2010; 39: 28593.
  • 6
    ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166: 11117.
  • 7
    Rasekaba T, Lee AL, Naughton MT et al. The six-minute walk test: a useful metric for the cardiopulmonary patient. Intern. Med. J. 2009; 39: 495501.
  • 8
    King TE Jr, Behr J, Brown KK et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2008; 177: 7581.
  • 9
    Raghu G, Brown KK, Costabel U et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2008; 178: 94855.
  • 10
    McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 225094.
  • 11
    Buch MH, Denton CP, Furst DE et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann. Rheum. Dis. 2007; 66: 16973.
  • 12
    Garin MC, Highland KB, Silver RM et al. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J. Rheumatol. 2009; 36: 3306.
  • 13
    Schoindre Y, Meune C, Dinh-Xuan AT et al. Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. J. Rheumatol. 2009; 36: 14815.
  • 14
    Impens AJ, Wangkaew S, Seibold JR. The 6-minute walk test in scleroderma—how measuring everything measures nothing. Rheumatology 2008; 47(Suppl. 5): v689.
  • 15
    Akdogan A, Kaya EB, Sahin A et al. Relationship between left ventricular diastolic dysfunction and six minute walk test in patients with systemic sclerosis. Int. J. Rheum. Dis. 2011; 14: 37983.
  • 16
    Mainguy V, Provencher S, Maltais F et al. Assessment of daily life physical activities in pulmonary arterial hypertension. PLoS ONE 2011; 6: e27993.
  • 17
    Lama VN, Flaherty KR, Toews GB et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168: 108490.
  • 18
    Flaherty KR, Andrei AC, Murray S et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am. J. Respir. Crit. Care Med. 2006; 174: 8039.
  • 19
    Swigris JJ, Zhou X, Wamboldt FS et al. Exercise peripheral oxygen saturation (SpO2) accurately reflects arterial oxygen saturation (SaO2) and predicts mortality in systemic sclerosis. Thorax 2009; 64: 62630.
  • 20
    Villalba WO, Sampaio-Barros PD, Pereira MC et al. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 2007; 131: 21722.